Network pharmacology reveals 114 therapeutic targets in COPD, highlighting AKT signaling pathways.
Manzufei decoction (MZFD) effectively treats COPD, but its mechanisms are unclear. Combining network pharmacology and experimental validation, we identified 168 bioactive components in MZFD and 265 potential targets. Network analysis pinpointed 4 core compounds. Comparing 1167 COPD-related targets revealed 114 overlapping therapeutic targets. Enrichment analysis implicated key pathways, notably AKT signaling. Molecular docking confirmed strong binding of quercetin to AKT and MUC5AC. Animal studies demonstrated that MZFD inhibits AKT signaling pathway activation, reduces MUC5AC protein expression in lung tissue and lung inflammation, thereby alleviating lung injury in AECOPD model rats.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: